Rona Therapeutics Closes $33 Million Series A for RNA Pipeline
publication date: Apr 8, 2022
Rona Therapeutics, a Shanghai RNA company founded last year, completed a $33 million Series A financing to build a delivery platform and initial therapeutic pipeline. The company will develop novel RNA medicines that have longer effects than current RNA products. Rona said its early candidates are modular, programmable molecules that target metabolic, neurological and ophthalmology diseases via different delivery systems. The round included well-known investors Lilly Asia Ventures, CMB International, Platanus, Fontus Capital and Lanting Capital. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.